Rhythm Biosciences Limited (ASX:RHY)

ALERT: Price-sensitive ASX Announcement for RHY

Current share price for RHY : $0.097 -0.103 (-51.50%)⁺

Announcement

First ColoSTAT Clinical Test Sale

Release

11 Mar 2026 8:28AM

Price at Release

$0.200

Full Release

Summary

Rhythm Biosciences Ltd (RHY) announced the completion of its first commercial sale of the ColoSTAT® colorectal cancer test, marking a significant milestone in the company's diagnostic operations. This test, designed for symptomatic individuals, was processed through Rhythm's validated clinical laboratory pathway, demonstrating its integration into routine clinical settings. The company plans to scale up test volumes through primary care physicians and the ColoSTAT® Access Program, which is already operational in five sites across Victoria and New South Wales. The successful sale affirms the potential of ColoSTAT® as a scalable and revenue-generating service, aligning with Rhythm's mission to provide early cancer detection solutions globally.

Key Points

First commercial sale of ColoSTAT® test completed.
ColoSTAT® test processed through a validated clinical pathway.
Test volumes to be scaled via primary care physicians and the ColoSTAT® Access Program.
Program operational in five sites across VIC and NSW.
Successful sale demonstrates ColoSTAT®'s scalability and revenue potential.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.